Virtual reality: A distraction intervention for chemotherapy
Virtual reality: A distraction intervention for chemotherapy
复制标题
DOI：
10.1188/07.onf.39-46
复制
发表时间：
2007-01-01
影响因子：
1.9
通讯作者：
Hood, Linda E.
中科院分区：
文献类型：
--
作者：
Schneider, Susan M.;Hood, Linda E.
目的/目标：探讨虚拟现实（VR）作为一种分心干预，以减轻症状困扰的成年人接受化疗治疗乳腺癌，结肠癌，肺癌。设计：交叉设计，其中参与者作为自己的控制。设置：门诊诊所在美国东南部的综合癌症中心。样本：123名接受初始化疗的成年人。研究方法：参与者被随机分配在一次化疗治疗期间接受VR牵引干预，然后在交替匹配的化疗治疗期间不接受干预（对照）。使用适应性症状困扰量表-2、修订的Piper疲劳量表和状态焦虑量表来测量症状困扰。使用在场问卷和开放式问卷来评估受试者的VR体验。探讨了癌症类型、年龄和性别对症状结局的影响。混合模型用于测试症状困扰水平的差异。主要研究变量：虚拟现实和症状困扰。结果：当使用VR时，患者对时间的感知发生了变化（p < 0.001），这验证了干预的分散能力。对干预的评估表明，患者认为头戴式设备易于使用，他们没有晕机，82%的人会再次使用VR。然而，分析表明没有显着差异的症状困扰立即或两天后化疗treatment.Conclusions：患者表示，使用VR的治疗似乎更短，VR的化疗治疗优于治疗没有分心干预。然而，积极的经历并没有导致症状困扰的减少。研究结果支持的想法，使用VR可以帮助使化疗治疗更耐受，但临床医生不应该假设使用VR将改善化疗相关的symptoms.Implications护理：患者发现使用VR在化疗治疗是愉快的。VR是一种可行且具有成本效益的牵引干预措施，可在临床环境中实施。
Purpose/Objectives: To explore virtual reality (VR) as a distraction intervention to relieve symptom distress in adults receiving chemotherapy treatments for breast, colon, and lung cancer.Design: Crossover design in which participants served as their own control.Setting: Outpatient clinic at a comprehensive cancer center in the southeastern United States. Sample: 123 adults receiving initial chemotherapy treatments. Methods: Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and then received no intervention (control) during an alternate matched chemotherapy treatment. The Adapted Symptom Distress Scale-2, Revised Piper Fatigue Scale, and State Anxiety Inventory were used to measure symptom distress. The Presence Questionnaire and an open-ended questionnaire were used to evaluate the subjects' VR experience. The influence of type of cancer, age, and gender on symptom outcomes was explored. Mixed models were used to test for differences in levels of symptom distress.Main Research Variables: Virtual reality and symptom distress.Findings: Patients had an altered perception of time (p < 0.001) when using VR, which validates the distracting capacity of the intervention. Evaluation of the intervention indicated that patients believed the head-mounted device was easy to use, they experienced no cybersickness, and 82% would use VR again. However, analysis demonstrated no significant differences in symptom distress immediately or two days following chemotherapy treatments.Conclusions: Patients stated that using VR made the treatment seem shorter and that chemotherapy treatments with VR were better than treatments without the distraction intervention. However, positive experiences did not result in a decrease in symptom distress. The findings support the idea that using VR can help to make chemotherapy treatments more tolerable, but clinicians should not assume that use of VR will improve chemotherapy-related symptoms.Implications for Nursing: Patients found using VR during chemotherapy treatments to be enjoyable. VR is a feasible and cost-effective distraction intervention to implement in the clinical setting.